In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

AZ gets antibody technology rights from Regeneron; deal terminated

Executive Summary

AstraZeneca has licensed from Regeneron (drug discovery for ophthalmic conditions, cancer, and inflammation) nonexclusive rights to the VelocImmune human monoclonal antibody discovery technology. AZ will develop therapeutic antibodies for undisclosed conditions.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register